InvestSMART

AFT Pharmaceuticals Limited (ASX:AFP)

ALERT: Price-sensitive ASX Announcement for AFP
Current share price for AFP : $3.010 0.3 (11.07%)+
Announcement
Release
20 Nov 2025 7:31AM
Price at Release
$2.710
Full Release
download
Summary
AFT Pharmaceuticals Limited reported an improved financial performance in its FY26 Interim Report for the six months ended 30 September 2025. The company achieved a profit after tax of $3.298 million compared to a loss in the previous period. Total revenue increased significantly to $114.942 million, driven by robust sales in Australia and New Zealand. The company managed net foreign exchange gains and maintained a comprehensive income of $3.362 million for equity holders. Despite paying dividends of $1.888 million, the cash flow from operating activities remained positive. AFT's joint venture with Hyloris Pharmaceuticals continues to progress, and the company remains vigilant in managing liquidity and capital.
Key Points
  • AFT Pharmaceuticals reported a profit after tax of $3.298 million for the six months ended 30 September 2025.
  • Total revenue for this period was $114.942 million, an increase from $86.713 million in the same period the previous year.
  • The company experienced net foreign exchange gains of $829k.
  • Dividends paid during this period amounted to $1.888 million.
  • The company reported a total comprehensive income of $3.362 million attributable to the equity holders.
  • The cash flow from operating activities was reported as a net inflow of $476k.
  • Total assets as of 30 September 2025 were valued at $171.622 million.
  • The company's financial performance benefited from increased sales across all regions, notably in Australia and New Zealand.
  • AFT Pharmaceuticals is involved in joint operations with Hyloris Pharmaceuticals for the Maxigesic IV product.
  • The company maintains a strong focus on managing its liquidity and capital structure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.